zum Inhalt springen

Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Genotyping and drug susceptibility profiling of Prototheca sp. strains isolated from cases of protothecosis in dogs (2025)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Proskurnicka, Angelika
    Iskra, Mateusz
    Wronka, Sylwia
    Bakuła, Zofia
    Danesi, Patrizia
    Rodrigues de Farias, Marconi
    Ramos Portilho, Fábio Vinícius
    Garcia Ribeiro, Márcio
    Rösler, Uwe (WE 10)
    Kano, Rui
    Malik, Richard
    Jagielski, Tomasz
    Quelle
    Journal of veterinary internal medicine
    Bandzählung: 39
    Heftzählung: 1
    Seiten: Artikel e17173 (7 Seiten)
    ISSN: 0891-6640
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://onlinelibrary.wiley.com/doi/10.1111/jvim.17173
    DOI: 10.1111/jvim.17173
    Pubmed: 39564964
    Kontakt
    Institut für Tier- und Umwelthygiene

    Robert-von-Ostertag-Str. 7-13
    14169 Berlin
    +49 30 838 51845
    tierhygiene@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Background

    Protothecosis in dogs is a rare, yet emerging disease, distinguished by its often-aggressive clinical course and high fatality rate. Our study was conducted to enhance treatment protocols for affected dogs by better understanding the genetic diversity and drug resistance patterns of Prototheca species.
    Objectives

    To identify species and drug susceptibility profiles of an international collection of 28 Prototheca strains isolated from cases of protothecosis in dogs.
    Animals

    None.
    Methods

    Retrospective study. Species-level identification was made for isolates from 28 dogs in 6 countries by molecular typing with the partial cytb gene as a marker. For the determination of minimum inhibitory concentrations (MICs) and minimum algicidal concentrations (MACs), the Clinical Laboratory Standards Institute (CLSI) protocol (M27-A3) was used.
    Results

    Prototheca bovis was the most prevalent species, accounting for 75% (21/28) of the cases, followed by P. wickerhamii (18%; 5/28) and P. ciferrii (7%; 2/28). Of the 6 drugs tested, efinaconazole (EFZ) was the most potent in vitro, with its median MIC and MAC values equal to 0.125 mg/L. The lowest activity was found for fluconazole (FLU), with MIC and MAC medians of 48 mg/L and 64 mg/L, respectively.
    Conclusions and Clinical Importance

    Our study identifies P. bovis as the species that most frequently causes protothecosis in dogs, which suggests the possibility of cross-species infection from other animals, especially cows. Additionally, it indicates that EFZ could be used in the treatment of infection in the colon.